CEL-SCI CorpNYSE American:CVM
- LAST PRICE0.8898
- TODAY'S CHANGE (%)-0.0081 (-0.9021%)
- Bid / Lots0.8905/ 19
- Ask / Lots0.9005/ 1
- Open / Previous Close0.8945 / 0.8979
- Day Range
- 52 Week Range
- Volume93,336
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CVM |
|---|---|---|
| 09:32 ET | 158 | 0.8945 |
| 09:50 ET | 1500 | 0.909699 |
| 09:54 ET | 100 | 0.9097 |
| 10:06 ET | 100 | 0.9025 |
| 10:08 ET | 1750 | 0.9 |
| 10:10 ET | 980 | 0.8979 |
| 10:21 ET | 100 | 0.8869 |
| 10:35 ET | 1500 | 0.8937 |
| 10:48 ET | 3000 | 0.89 |
| 10:53 ET | 250 | 0.900499 |
| 10:57 ET | 100 | 0.89425 |
| 11:06 ET | 100 | 0.89425 |
| 11:09 ET | 190 | 0.9005 |
| 11:15 ET | 568 | 0.8901 |
| 11:20 ET | 1610 | 0.9 |
| 11:22 ET | 1200 | 0.8998 |
| 11:24 ET | 300 | 0.8998 |
| 11:27 ET | 523 | 0.8927 |
| 11:31 ET | 100 | 0.8986 |
| 11:36 ET | 599 | 0.8942 |
| 11:40 ET | 800 | 0.894 |
| 11:42 ET | 1002 | 0.89425 |
| 11:47 ET | 423 | 0.888 |
| 11:49 ET | 300 | 0.8899 |
| 11:51 ET | 330 | 0.8898 |
| 11:54 ET | 1300 | 0.8899 |
| 11:56 ET | 1500 | 0.8889 |
| 12:00 ET | 300 | 0.8899 |
| 12:03 ET | 300 | 0.8899 |
| 12:05 ET | 115 | 0.8889 |
| 12:07 ET | 300 | 0.8899 |
| 12:14 ET | 300 | 0.8899 |
| 12:16 ET | 3000 | 0.8899 |
| 12:18 ET | 300 | 0.8899 |
| 12:20 ET | 600 | 0.888001 |
| 12:21 ET | 900 | 0.888 |
| 12:23 ET | 300 | 0.88745 |
| 12:25 ET | 350 | 0.887449 |
| 12:27 ET | 100 | 0.8898 |
| 12:30 ET | 300 | 0.8898 |
| 12:32 ET | 100 | 0.8898 |
| 12:36 ET | 460 | 0.886033 |
| 12:38 ET | 300 | 0.8874 |
| 12:39 ET | 100 | 0.8898 |
| 12:41 ET | 100 | 0.8898 |
| 12:43 ET | 500 | 0.8898 |
| 12:45 ET | 200 | 0.8874 |
| 12:48 ET | 300 | 0.8898 |
| 12:50 ET | 100 | 0.8898 |
| 12:52 ET | 282 | 0.8863 |
| 12:54 ET | 100 | 0.8898 |
| 12:59 ET | 3410 | 0.885 |
| 01:01 ET | 2000 | 0.8864 |
| 01:03 ET | 200 | 0.8879 |
| 01:08 ET | 100 | 0.8879 |
| 01:10 ET | 400 | 0.8878 |
| 01:14 ET | 100 | 0.8878 |
| 01:17 ET | 100 | 0.8878 |
| 01:19 ET | 300 | 0.8878 |
| 01:21 ET | 100 | 0.8878 |
| 01:24 ET | 100 | 0.8877 |
| 01:28 ET | 100 | 0.8877 |
| 01:32 ET | 100 | 0.8877 |
| 01:33 ET | 1700 | 0.8871 |
| 01:35 ET | 600 | 0.8877 |
| 01:39 ET | 212 | 0.8877 |
| 01:42 ET | 100 | 0.8872 |
| 01:44 ET | 100 | 0.8877 |
| 01:46 ET | 400 | 0.8877 |
| 01:50 ET | 100 | 0.8877 |
| 01:51 ET | 1600 | 0.8874 |
| 01:53 ET | 200 | 0.8875 |
| 01:55 ET | 1081 | 0.8875 |
| 02:04 ET | 100 | 0.8874 |
| 02:06 ET | 100 | 0.8875 |
| 02:08 ET | 469 | 0.8874 |
| 02:11 ET | 300 | 0.8876 |
| 02:18 ET | 300 | 0.8876 |
| 02:22 ET | 1799 | 0.8876 |
| 02:24 ET | 1500 | 0.8863 |
| 02:26 ET | 250 | 0.886 |
| 02:27 ET | 375 | 0.8851 |
| 02:29 ET | 230 | 0.8863 |
| 02:31 ET | 300 | 0.8863 |
| 02:33 ET | 200 | 0.8863 |
| 02:36 ET | 995 | 0.8831 |
| 02:40 ET | 300 | 0.8876 |
| 02:44 ET | 3430 | 0.8853 |
| 02:47 ET | 200 | 0.8875 |
| 02:51 ET | 300 | 0.8853 |
| 02:58 ET | 300 | 0.8874 |
| 03:02 ET | 222 | 0.8874 |
| 03:05 ET | 278 | 0.8874 |
| 03:07 ET | 100 | 0.8862 |
| 03:09 ET | 222 | 0.8874 |
| 03:14 ET | 1150 | 0.8862 |
| 03:20 ET | 300 | 0.8874 |
| 03:21 ET | 300 | 0.8874 |
| 03:23 ET | 2131 | 0.8874 |
| 03:25 ET | 696 | 0.8899 |
| 03:32 ET | 2900 | 0.8899 |
| 03:34 ET | 300 | 0.8899 |
| 03:36 ET | 100 | 0.8899 |
| 03:38 ET | 500 | 0.8899 |
| 03:39 ET | 700 | 0.8898 |
| 03:43 ET | 200 | 0.8899 |
| 03:45 ET | 1393 | 0.8899 |
| 03:48 ET | 280 | 0.8899 |
| 03:50 ET | 300 | 0.885101 |
| 03:52 ET | 427 | 0.8898 |
| 03:54 ET | 934 | 0.8898 |
| 03:56 ET | 500 | 0.8898 |
| 03:57 ET | 1500 | 0.89 |
| 03:59 ET | 14974 | 0.8898 |
Oct 22, 2024
Oct 1, 2024
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine(R) in Head and Neck Cancer, from 6:00AM ET on Tuesday Oct 01, 2024 by Dow Jones
6:00AM ET on Tuesday Oct 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CEL-SCI Corp | 55.2M | -1.5x | --- |
Vor Biopharma Inc | 54.6M | -0.5x | --- |
Actinium Pharmaceuticals Inc | 55.5M | -1.2x | --- |
OS Therapies Inc | 54.4M | -8.7x | --- |
Gain Therapeutics Inc | 55.7M | -1.9x | --- |
Quince Therapeutics Inc | 56.7M | -1.3x | --- |
Company Information
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
Contact Information
- Headquarters
- SUITE 802, 8229 BOONE BLVD .VIENNA, VA, United States 22182
- Phone
- 703-506-9460
- Fax
- 703-506-9471
Executives
- Independent Chairman of the Board
- Robert Watson
- Chief Executive Officer, Chief Financial Officer, Treasurer, Director
- Geert Kersten
- Senior Vice President - Operations, Corporate Secretary
- Patricia Prichep
- Senior Vice President - Regulatory Affairs
- John Cipriano
- Senior Vice President - Research, Cellular Immunology
- Daniel Zimmerman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.5M |
CEL-SCI Corp does not pay a dividend. | |
Beta | 0.67 |
EPS | $-0.58 |
Book Value | $0.28 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
